PMC:7600245 / 17160-17542 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T64","span":{"begin":328,"end":336},"obj":"Disease"}],"attributes":[{"id":"A64","pred":"mondo_id","subj":"T64","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Interestingly, a recent open-label randomized controlled trial (NCT04276688; n = 127) indicated that early triple antiviral therapy of INF-β 1b, ribavirin, and lopinavir/ritonavir was safe and superior to lopinavir/ritonavir alone in alleviating the symptoms and shortening the duration of viral shedding and hospitalization in COVID-19 patients with mild to moderate symptoms [59]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T156","span":{"begin":15,"end":16},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T157","span":{"begin":29,"end":34},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T158","span":{"begin":142,"end":143},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"}],"text":"Interestingly, a recent open-label randomized controlled trial (NCT04276688; n = 127) indicated that early triple antiviral therapy of INF-β 1b, ribavirin, and lopinavir/ritonavir was safe and superior to lopinavir/ritonavir alone in alleviating the symptoms and shortening the duration of viral shedding and hospitalization in COVID-19 patients with mild to moderate symptoms [59]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T176","span":{"begin":29,"end":34},"obj":"Chemical"},{"id":"T177","span":{"begin":114,"end":123},"obj":"Chemical"},{"id":"T178","span":{"begin":135,"end":138},"obj":"Chemical"},{"id":"T179","span":{"begin":145,"end":154},"obj":"Chemical"},{"id":"T180","span":{"begin":160,"end":179},"obj":"Chemical"},{"id":"T181","span":{"begin":160,"end":169},"obj":"Chemical"},{"id":"T182","span":{"begin":170,"end":179},"obj":"Chemical"},{"id":"T183","span":{"begin":205,"end":224},"obj":"Chemical"},{"id":"T184","span":{"begin":205,"end":214},"obj":"Chemical"},{"id":"T185","span":{"begin":215,"end":224},"obj":"Chemical"}],"attributes":[{"id":"A176","pred":"chebi_id","subj":"T176","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A177","pred":"chebi_id","subj":"T177","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A178","pred":"chebi_id","subj":"T178","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A179","pred":"chebi_id","subj":"T179","obj":"http://purl.obolibrary.org/obo/CHEBI_63580"},{"id":"A180","pred":"chebi_id","subj":"T180","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A181","pred":"chebi_id","subj":"T181","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A182","pred":"chebi_id","subj":"T182","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A183","pred":"chebi_id","subj":"T183","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A184","pred":"chebi_id","subj":"T184","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A185","pred":"chebi_id","subj":"T185","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"}],"text":"Interestingly, a recent open-label randomized controlled trial (NCT04276688; n = 127) indicated that early triple antiviral therapy of INF-β 1b, ribavirin, and lopinavir/ritonavir was safe and superior to lopinavir/ritonavir alone in alleviating the symptoms and shortening the duration of viral shedding and hospitalization in COVID-19 patients with mild to moderate symptoms [59]."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T26","span":{"begin":290,"end":304},"obj":"http://purl.obolibrary.org/obo/GO_0019076"}],"text":"Interestingly, a recent open-label randomized controlled trial (NCT04276688; n = 127) indicated that early triple antiviral therapy of INF-β 1b, ribavirin, and lopinavir/ritonavir was safe and superior to lopinavir/ritonavir alone in alleviating the symptoms and shortening the duration of viral shedding and hospitalization in COVID-19 patients with mild to moderate symptoms [59]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T128","span":{"begin":0,"end":382},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Interestingly, a recent open-label randomized controlled trial (NCT04276688; n = 127) indicated that early triple antiviral therapy of INF-β 1b, ribavirin, and lopinavir/ritonavir was safe and superior to lopinavir/ritonavir alone in alleviating the symptoms and shortening the duration of viral shedding and hospitalization in COVID-19 patients with mild to moderate symptoms [59]."}

{"project":"LitCovid-PubTator","denotations":[{"id":"420","span":{"begin":337,"end":345},"obj":"Species"},{"id":"429","span":{"begin":145,"end":154},"obj":"Chemical"},{"id":"430","span":{"begin":160,"end":179},"obj":"Chemical"},{"id":"431","span":{"begin":205,"end":224},"obj":"Chemical"},{"id":"434","span":{"begin":328,"end":336},"obj":"Disease"}],"attributes":[{"id":"A420","pred":"tao:has_database_id","subj":"420","obj":"Tax:9606"},{"id":"A429","pred":"tao:has_database_id","subj":"429","obj":"MESH:D012254"},{"id":"A430","pred":"tao:has_database_id","subj":"430","obj":"MESH:C558899"},{"id":"A431","pred":"tao:has_database_id","subj":"431","obj":"MESH:C558899"},{"id":"A434","pred":"tao:has_database_id","subj":"434","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Interestingly, a recent open-label randomized controlled trial (NCT04276688; n = 127) indicated that early triple antiviral therapy of INF-β 1b, ribavirin, and lopinavir/ritonavir was safe and superior to lopinavir/ritonavir alone in alleviating the symptoms and shortening the duration of viral shedding and hospitalization in COVID-19 patients with mild to moderate symptoms [59]."}